Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Bull Cancer. 2007 Jul;94(7 Suppl):F29-34.

[Interleukin-6 implication in prostate cancer].

[Article in French]

Author information

  • 1Service de thérapie cellulaire et d'hématologie clinique adultes, Pavillon Villemin-Pasteur, Hôtel-Dieu boulevard Léon-Malfreyt, 63058 Clermont-Ferrand. acabrespine@chu-clermontferrand.fr

Abstract

Interleukin-6 (IL-6) is secreted in great quantity in prostatic tumoral glandular tissue with a significant higher rate in hormono-refractory phase. Importance of IL-6 dependent mechanism in prostate cancer progression is well argued. IL-6 seems to be implicated in androgen receptor activation in lack of steroid ligand, apoptosis decrease and increase of invasive capacity and angiogenesis via three major signaling pathways: MAPK, STAT3 and PI3K-Akt. As AR is a key factor of prostate cancer progression, IL-6 implication in this activation underlines IL-6 importance in prostate cancer. IL-6 also induces neuroendocrine differentiation. This phenomenon received a detailed attention because it would take part in pathogenicity and progression of prostate cancer. Although complementary studies seem necessary, taking into account its strong implication in prostate cancer progression, IL-6 seems to be a new potential therapeutic target of prostate cancer.

PMID:
17845991
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk